Home Healthcare Pharmaceuticals Intravenous Iron Drugs Market

Intravenous Iron Drugs Market Size, Share & Trends Analysis Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Intravenous Iron Drugs Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Iron Dextran
    2. Iron Sucrose
    3. Ferric Carboxymaltose
  2. Intravenous Iron Drugs Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Chronic Kidney Disease
    2. Inflammatory Bowel Disease
    3. Cancer
  3. Regional Intravenous Iron Drugs Market
    1. North America
      1. North America Intravenous Iron Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
      2. North America Intravenous Iron Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Disease
        2. Inflammatory Bowel Disease
        3. Cancer
      3. U.S.
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      4. Canada
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
    2. Europe
      1. Europe Intravenous Iron Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
      2. Europe Intravenous Iron Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Disease
        2. Inflammatory Bowel Disease
        3. Cancer
      3. U.K.
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      4. Germany
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      5. France
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      6. Spain
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      7. Italy
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      8. Russia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      9. Nordic
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      10. Benelux
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      11. Rest of Europe
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
    3. APAC
      1. APAC Intravenous Iron Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
      2. APAC Intravenous Iron Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Disease
        2. Inflammatory Bowel Disease
        3. Cancer
      3. China
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      4. Korea
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      5. Japan
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      6. India
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      7. Australia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      8. Singapore
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      9. Taiwan
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      10. South East Asia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      11. Rest of Asia-Pacific
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
    4. Middle East and Africa
      1. Middle East and Africa Intravenous Iron Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
      2. Middle East and Africa Intravenous Iron Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Disease
        2. Inflammatory Bowel Disease
        3. Cancer
      3. UAE
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      4. Turkey
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      5. Saudi Arabia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      6. South Africa
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      7. Egypt
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      8. Nigeria
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      9. Rest of MEA
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
    5. LATAM
      1. LATAM Intravenous Iron Drugs Market By Product 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
      2. LATAM Intravenous Iron Drugs Market By Application 2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Disease
        2. Inflammatory Bowel Disease
        3. Cancer
      3. Brazil
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      4. Mexico
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      5. Argentina
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      6. Chile
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      7. Colombia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
      8. Rest of LATAM
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Chronic Kidney Disease
        5. Inflammatory Bowel Disease
        6. Cancer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.